Clinigen Group PLC’s “Buy” Rating Reaffirmed at Oriel Securities Ltd (CLIN)
Clinigen Group PLC (LON:CLIN)‘s stock had its “buy” rating reaffirmed by equities researchers at Oriel Securities Ltd in a research report issued on Tuesday. They currently have a GBX 650 ($10.79) price objective on the stock. Oriel Securities Ltd’s price objective would indicate a potential upside of 49.49% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Investec raised their price target on shares of Clinigen Group PLC from GBX 497 ($8.25) to GBX 512 ($8.50) in a research note on Wednesday, August 20th. They now have a “buy” rating on the stock. Separately, analysts at Peel Hunt raised their price target on shares of Clinigen Group PLC from GBX 690 ($11.45) to GBX 710 ($11.78) in a research note on Wednesday, August 20th. They now have a “buy” rating on the stock. Finally, analysts at Numis Securities Ltd reiterated a “buy” rating on shares of Clinigen Group PLC in a research note on Wednesday, August 20th. They now have a GBX 650 ($10.79) price target on the stock. Five investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average target price of GBX 592.20 ($9.83).
Shares of Clinigen Group PLC (LON:CLIN) opened at 444.46 on Tuesday. Clinigen Group PLC has a 52-week low of GBX 354.92 and a 52-week high of GBX 690.00. The stock’s 50-day moving average is GBX 392. and its 200-day moving average is GBX 460.6.
Clinigen Group plc (LON:CLIN) is a specialty pharmaceuticals and services business company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.